Cite
Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.
MLA
Goldman, S., et al. “Rituximab and FAB/LMB 96 Chemotherapy in Children with Stage III/IV B-Cell Non-Hodgkin Lymphoma: A Children’s Oncology Group Report.” Leukemia (08876924), vol. 27, no. 5, May 2013, pp. 1174–77. EBSCOhost, https://doi.org/10.1038/leu.2012.255.
APA
Goldman, S., Smith, L., Anderson, J. R., Perkins, S., Harrison, L., Geyer, M. B., Gross, T. G., Weinstein, H., Bergeron, S., Shiramizu, B., Sanger, W., Barth, M., Zhi, J., & Cairo, M. S. (2013). Rituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children’s Oncology Group report. Leukemia (08876924), 27(5), 1174–1177. https://doi.org/10.1038/leu.2012.255
Chicago
Goldman, S, L Smith, J R Anderson, S Perkins, L Harrison, M B Geyer, T G Gross, et al. 2013. “Rituximab and FAB/LMB 96 Chemotherapy in Children with Stage III/IV B-Cell Non-Hodgkin Lymphoma: A Children’s Oncology Group Report.” Leukemia (08876924) 27 (5): 1174–77. doi:10.1038/leu.2012.255.